View in Browser
Replacement Test: Cytochrome P450-2C19 (CYP2C19) Nucleic Acid Detection Tests
The Diagnostic Molecular Pathology Division will replace the current CYP2C19 assay that is performed on the Spartan Rx platform to a TaqMan-based platform. This change is necessary as the Spartan Rx assay is no longer being manufactured.

Methodology and reporting:
TaqMan-mediated PCR amplification is done on DNA extracted from peripheral blood. This test is designed to identify *2, *3, and *17 alleles. Thus, a *1 genotype indicates the absence of *2, *3, and *17 alleles only and does not preclude the existence other 2C19 allelic variants that may alter activity of the enzyme.

An interpretive report will be provided.

Effective date: Sept. 17, 2021

Specimen requirements:

Collect: 4.0 mL of blood in in EDTA tube (lavender or pink top) preferred. ACD (light yellow top) or Sodium Citrate (blue top) also acceptable.

Minimum volume: 0.5 mL whole blood

Test code: 2C19

CPT code: 81225

Turnaround time (TAT):
Routine: 3-7 days
Set up days: Twice a week

Ambient: 24 hours
Refrigerated: 7 days from collection date
Frozen: Unacceptable

Rejection criteria:
Specimens that exceed stated stability, unlabeled/mislabeled specimens, specimens drawn in incorrect collection tubes.

A summary of all tests offered by our laboratory services can be found here:


Jeff Chan, MD, PhD
Division of Diagnostic Molecular Pathology

Edwin S. Monuki, MD, PhD
Department of Pathology & Laboratory Medicine

© 2021 The Regents of the University of California. All rights reserved. Proprietary and Confidential. For Internal Distribution Only.